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Abstract 
Brain metastases develop frequently in patients with breast cancer, and present a pressing 
therapeutic challenge. Expression of vascular cell adhesion molecule 1 (VCAM-1) is upregulated on 
brain endothelial cells during the early stages of metastasis and provides a target for the detection 
and treatment of early brain metastases. The aim of this study was to use a model of early brain 
metastasis to evaluate the efficacy of α-emitting radionuclides, 149Tb, 211At, 212Pb, 213Bi and 225Ac; 
β-emitting radionuclides, 90Y, 161Tb and 177Lu; and Auger electron (AE)-emitters 67Ga, 89Zr, 111In and 
124I, for targeted radionuclide therapy (TRT).  
METHODS: Histologic sections and two photon microscopy of mouse brain parenchyma were 
used to inform a cylindrical vessel geometry using the Geant4 general purpose Monte Carlo (MC) 
toolkit with the Geant4-DNA low energy physics models. Energy deposition was evaluated as a 
radial function and the resulting phase spaces were superimposed on a DNA model to estimate 
double-strand break (DSB) yields for representative β- and α-emitters, 177Lu and 212Pb. Relative 
biological effectiveness (RBE) values were determined by only evaluating DNA damage due to 
physical interactions. 
RESULTS: 177Lu produced 2.69 ± 0.08 DSB per GbpGy, without significant variation from the 
lumen of the vessel to a radius of 100 µm. The DSB yield of 212Pb included two local maxima 
produced by the 6.1 MeV and 8.8 MeV α-emissions from decay products, 212Bi and 212Po, with yields 
of 7.64 ± 0.12 and 9.15 ± 0.24 per GbpGy, respectively. Given its higher DSB yield 212Pb may be 
more effective for short range targeting of early micrometastatic lesions than 177Lu.  
CONCLUSION: MC simulation of a model of early brain metastases provides invaluable insight 
into the potential efficacy of α-, β- and AE-emitting radionuclides for TRT. 212Pb, which has the 
attributes of a theranostic radionuclide since it can be used for SPECT imaging, showed a favorable 
dose profile and RBE. 
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Introduction 
The development of brain metastases is a 
frequent complication of several common cancers. For 
example, it occurs in ~30% of breast cancer patients, 









triple-negative and human epidermal growth factor 
receptor 2 (HER2)-positive disease [1]. The 
management of brain metastases is complex and, 
depending on the clinical situation, may include 
surgical resection, whole-brain radiation therapy 
(WBRT), stereotactic radiosurgery (SRS), 
chemotherapy and molecularly targeted agents or 
combinations of these. Patients with multiple 
metastases, uncontrolled systemic disease, and poor 
functional status are typically treated with WBRT 
alone, whereas surgery and SRS may be used to 
achieve local control in those patients with single or 
oligo-metastases and good functional status [2]. 
Surgery and WBRT are sometimes used in 
conjunction with chemotherapy, anti-estrogen or 
HER2-targeted therapies depending on patient and 
tumor characteristics [3-7]. Despite these therapeutic 
options, brain metastases remain a significant cause of 
morbidity and mortality among breast cancer patients 
and novel approaches to their management are 
needed. 
Targeted radionuclide therapy (TRT) allows 
precise delivery of systemically administered 
radioactivity to disseminated cancer cells. Unlike 
conventional, non-radiolabeled targeted therapies, 
which only affect cells that express the relevant 
molecular target [8], TRT may damage tumour cells 
even if they lack the specific tumor-associated antigen 
or receptor through cross-fire or bystander effects [9]. 
This unique feature extends the tumoricidal capacity 
of TRT beyond the physical location of the 
radionuclide [10]. An added advantage of this therapy 
is that many of the α-, β- and Auger electron 
(AE)-emitting radionuclides used for TRT permit 
simultaneous diagnostic radioimaging through 
emission of γ and annihilation photons that can be 
detected using single photon emission computed 
tomography (SPECT) or positron emission 
tomography (PET). The use of TRT in the treatment of 
primary brain tumors or metastasis has been reported 
previously. 131I-labeled L19SIP (radretumab) is a small 
immunoprotein directed against the extracellular-B 
domain of fibronectin, which is present in the 
extracellular matrix surrounding newly formed blood 
vessels, such as in solid tumors. L19SIP has shown 
therapeutic benefit in patients with brain metastases 
originating from non-small cell lung cancer or breast 
carcinoma [11, 12]. This radiopharmaceutical is being 
developed as a treatment in combination with WBRT 
and as a companion PET imaging agent; 124I-labeled 
L19SIP is used to inform dosimetry of the therapeutic 
[13]. TRT has also been described in the treatment of 
high grade gliomas. For example, substance P, a 
ligand of the transmembrane receptor neurokinin 
type-1 (NK-1), which is consistently overexpressed in 
gliomas, has been labeled with 90Y, 177Lu or 213Bi, and 
has shown little toxicity and improved neurologic 
status in clinical trials [14, 15]. Antitenascin antibodies 
labelled with 131I, 90Y or 211At have been instilled into 
resection cavities following surgery for malignant 
central nervous system (CNS) tumors [16-18]. Both β- 
(131I and 90Y) and α- (211At) emitting constructs were 
well tolerated with little associated toxicity, promising 
antitumor benefit in patients. 
It is known that vascular cell adhesion molecule 
1 (VCAM-1) is highly expressed on endothelial cells 
during the initial stages of metastatic seeding to the 
brain [19], and plays a key role in tumor cell adhesion 
to the vascular endothelium and subsequent 
transendothelial migration [19, 20]. VCAM-1 could, 
therefore, act as a target for TRT of early stage brain 
metastases. Indeed, a radiolabeled VCAM-1 specific 
peptide has been identified as a viable imaging probe 
in a mouse model of ovarian cancer peritoneal 
metastasis [21]. Therefore, a theranostic radionuclide 
targeted to VCAM-1 could be used to simultaneously 
image and treat early brain metastases. However, to 
avoid normal brain cell damage and associated loss of 
brain function, the range of the particulate emissions 
from the radionuclide used should reflect the extent of 
metastasis penetration into the brain parenchyma [22] 
while still providing a high absorbed radiation dose 
and uniform dose distribution [23]. Thus, a 
biologically informed Monte Carlo (MC) model could 
provide invaluable insights into the selection of a 
radionuclide with a favourable dose profile. 
The choice of therapeutic radionuclides is often 
limited by commercial availability and chemical 
suitability for attachment to a particular carrier 
molecule. In this paper we evaluate the merits of 
commercially available radionuclides for early brain 
metastasis targeting, by considering their absorbed 
dose profiles and DNA damaging potential in a 
geometric model that is based on information derived 
from a murine model of brain metastases (Fig. 1). 
Event-by-event MC simulation of the complete 
radiation spectra of α-emitting radionuclides, namely 
149Tb, 211At, 212Pb, 213Bi and 225Ac; β-emitting 
radionuclides, 90Y, 161Tb and 177Lu; and AE-emitters 
67Ga, 89Zr, 111In and 124I, affords exquisite detail of their 
absorbed dose profiles and obviates the need to 
evaluate all of their effects individually in animal 
models. Using an atomistic model to simulate 
radiation-DNA interaction [24, 25], we are then able to 
evaluate the merits of the most favourable 
radionuclides for potential use in the treatment of 
early brain metastasis. 
 





Material and Methods 
In Vivo Models 
A GFP-tagged sub-clone of a triple negative 
human breast carcinoma cell line that preferentially 
metastasizes to the brain, MDA231BR, was used [19, 
26, 27]. Briefly, female SCID mice (n = 3), 7–8 weeks 
old, were anesthetized and received intra-cardiac 
injections of 1×105 MDA231BR cells in 100 µL PBS. At 
21 days after tumour cell injection, animals were 
terminally anaesthetized with 0.3 mL sodium 
pentobarbitone and transcardially perfusion-fixed 
using intra-cardiac injections of 0.9% heparinised 
saline followed by 10 mL of periodate lysine 
paraformaldehyde with 0.01% glutaraldehyde. Brains 
were cryoprotected, frozen in isopentane and 10-20 
µm thick sections were cut. All in vivo experiments 
were approved by the UK Home Office and the 
French regional committee on animal ethics 
(CENOMEXA). 
Immunohistochemistry 
The expression of VCAM-1 and CD31, a marker 
of endothelial cells, were assessed in brain tissue as 
previously described [19, 20]. Briefly, sections were 
rehydrated in phosphate-buffered saline (PBS; 
Thermo Fisher Scientific, UK; pH 7.4), quenched with 
1% hydrogen peroxide (Sigma Aldrich, UK) in 
methanol and blocked in 10% normal goat serum for 
VCAM-1 expression or normal horse serum for CD31. 
Primary antibody was incubated overnight at 4° C, 
using 1:250 dilution for VCAM-1 (rat anti-mouse, 
Cambridge Bioscience, 1510-14) or 1:100 dilution for 
CD31 (goat anti-mouse, Bio-Techne R&D, AF3628). 
Samples were then incubated for 1 h at room 
temperature using a biotinylated goat anti-rat (1:100, 
vectorlabs, CA, USA) or biotinylated horse anti-goat 
secondary antibody (1:200, vectorlabs). After 
amplification using the ABC reaction, staining was 
detected using standard DAB/hydrogen reaction. 
Sections were counterstained using cresyl violet and 
mounted using DPX mounting solution (Thermo 
Fisher Scientific, UK). Slides were scanned using an 
Aperio brightfield scanner (Leica Biosystems) and 
analysed using ImageScope®. Histologic sections of 
mouse brain parenchyma were used to measure the 
diameter of CD31-stained blood vessels and the depth 
of cancer cell infiltration into brain tissue. These data 
were used to generate a geometric model for MC 
simulation that reflected the dimensions of brain 
metastases at 21 days following intracardiac injection 
in the MDA231BR model. 
 
 
Figure 1. (A) VCAM-1 mediated cancer infiltration into the brain parenchyma; anti-VCAM-1 radionuclide immunoconstruct binds VCAM-1 and irradiates the 
metastasis. (B) Geant4 geometry: The inner cylinder (red) depicts the vessel and the outer cylinder (blue) the volume in which energy deposition was recorded. The 
disk around the vessel shows the volume where Geant4-DNA physics models were applied and (C) contains the atomistic geometrical model of the B-DNA 
configuration for DNA [25]. Each VOI is filled with 30 nm chromatin fibers (5.47 Gbp). These are formed by a helix with 6 nucleosomes/turn. Two adjacent 
nucleosomes are bound by a DNA fragment containing 46 bp. (1) Fragment of the 30 nm chromatin fiber containing 6 nucleosomes (one helix pitch). (2) Two 
helicoidal loops with 77 bp each folded around a sphere simulating a histone. (3) Sample of a straight fragment of the B-DNA double helix containing 20 bp. 





Two Photon microscopy 
Animals (n = 3) were injected intracardially with 
GFP-positive MDA231BR cells. After 21 days, animals 
were anesthetized using isoflurane (5% in an O2/N2O 
mixture for induction and 1.0-1.5% during surgery). 
Analgesic (tolfedine, 4 mg/kg), was administrated 
subcutaneously. The rectal temperature was 
monitored and maintained at 37.5°C using a heating 
pad. A circular region over the somatosensory cortex 
(2 x 2 mm in size) was gently thinned to ~50 µm with a 
high speed drill. The thinned region was coated with 
a drop of cyanoacrylate glue to facilitate a viewing 
window [28]. In vivo two-photon imaging was 
performed on a Leica DM6000 stand (CYCERON 
biomedical imaging platform) with a 25x/0.95 water 
HCX IRAPO objective and laser excitation 
wavelength centered at 900 nm. Animals were 
positioned during microscopy using a custom built 
cradle and received an intravenous (i.v.) injection of 
tetramethyl rhodamine isothiocyanate 
(TRITC-dextran, 70 kDA, 10 mg/mL) (Sigma-Aldrich) 
to visualize the vascular compartment. 
Monte Carlo Modeling – Geant4-DNA 
Monte Carlo modeling of radiation transport 
was performed using the Geant4.10.02.p02 toolkit 
[29]. The coupled transport of charged particles and 
photons were evaluated for α-emitting radionuclides 
(149Tb, 211At, 212Pb, 213Bi and 225Ac), β-emitting 
radionuclides (90Y, 161Tb and 177Lu) and AE-emitters 
(67Ga, 89Zr, 111In and 124I). Energy losses were tallied 
when the complete decay spectra of each 
radionuclide, including daughters in the various α 
decay schemes, interacted with liquid water (density 
scaled to 1.06 g/cm3). Each energy deposit was 
associated with a particle produced in the decay, 
differentiating electron ionization events downstream 
of α-particles or electrons produced from the initial 
decay. The geometry consisted of a cylinder 
representing a blood vessel with point sources 
randomly distributed on its luminal surface, 
simulating binding of a radiolabeled anti-VCAM-1 
antibody to the VCAM-1 receptor (Fig. 1).  
Energy deposits were recorded in a 3.5 μm thick 
virtual disk, centred with respect to the vessel 
volume, extending from the vessel wall to a radius of 
110 μm (Fig. 1B). This geometry was specifically 
chosen such that recorded energy deposition could be 
superimposed on an atomistic resolution DNA 
geometrical model contained in a rectangular prism 
(Fig. 1C) [30]. The Geant4-DNA models were used for 
electromagnetic processes involving electron energies 
< 1 MeV in this volume as well as a buffer region 
extending at least 3.0 μm in all directions. Throughout 
the entire simulation, the Geant4-DNA processes 
were enabled for helium, single-ionized helium (α+), 
and doubly-ionized helium (α) particles. The 
Livermore electromagnetic models were used for 
γ-rays in the whole simulation volume, for high 
energy electrons in the target plus buffer region, and 
for all electrons outside this region. The secondary 
electron production threshold was set to 990 eV 
outside the target plus buffer region, which 
corresponds to a range of approximately 1 µm. 
Electrons were tracked down to an energy of 8.0 eV, at 
which point the energy was deposited locally. Energy 
deposition in this geometry was converted to 
absorbed dose (Gy) and binned at 1 µm intervals. 
Statistical uncertainties were calculated by dividing 
the simulation results into batches (5 for the Geant4 
simulations and 10 for the DNA damage simulations) 
and calculating the standard deviation of the results. 
The effect of variation in vessel diameter and active 
vessel length (i.e., the longitudinal section of the 
vessel with randomly distributed point sources) on 
absorbed dose calculation was also considered. 
Cylinder diameters were 5, 10 and 15 µm and the 
active vessel length for a cylinder of diameter 15 µm 
was varied from 20 to 100 µm. The DNA strand break 
yields of a selected α-emitter, 212Pb, and β-emitter, 
177Lu, were evaluated from these simulations.  
To have comparable statistical uncertainties in 
the DSB yields for 177Lu and 212Pb, the number of 
events for 177Lu was increased to achieve comparable 
dose. Energy deposition phase spaces for 177Lu and 
212Pb were superimposed on the DNA geometrical 
model to estimate direct DSB yields, reported per unit 
of absorbed dose (Gy) and 109 base pairs (Gbp). The 
DNA geometrical model was filled with chromatin 
fibers containing 5.47 Gbp. Each rectangular prism 
(3.085 x 3.085 x 3.383 µm3) represents a volume of 
interest (VOI), which were spaced 5 µm apart radially 
within the disk. The number of VOIs varied based on 
the vessel radius. A single strand break (SSB) was 
recorded if an energy transfer greater than 8.0 eV 
occurs within a DNA sugar-phosphate group. A DSB 
was recorded if two SSB on opposed DNA strands 
were separated by no more than 10 bp [31]. In this 
study, DSB yield was used as the biological endpoint 
to estimate the relative biological effectiveness (RBE) 
of the radionuclides being investigated. RBE was 
determined with respect to 60Co radiation, for which 
the DSB yield is 3.60 ± 0.05 (per GbpGy) [32, 33]. 
Results 
Immunohistochemistry 
In total, 929 brain tissue vessels identified by 
CD31 immunostaining from 3 animals were analysed 





(Fig. 2A). To account for variation in vessel diameter 
in the mouse model of brain metastasis and to provide 
realistic dimensions for MC simulation, vessel 
diameters were grouped as < 5 μm, 5-10 μm, and > 10 
μm, with corresponding mean ± SD diameters 
measured as 4.04 ± 0.64 μm, 6.16 ± 1.00 μm and 13.25 ± 
3.19 μm. The maximal penetration of MDA231BR cells 
into the brain parenchyma was evaluated at day 21. In 
mice that received intracardiac injections of 
MDA231BR cells, tumors grew into the cerebral 
parenchyma from blood vessels with maximum 
penetration depths of 30.6 µm, 47.8 µm and 23.2 µm 
from the vessel wall, for vessel diameters of < 5 µm, 
between 5 and 10 µm, and > 10 µm respectively (Fig. 
2B). Two photon microscopy images (Fig. 2C) 
confirmed the penetration depths and co-optive 
growth of MDA231BR-GFP cells around vessels. 
Dose deposition profiles  
A summary of the normalized absorbed dose 
profiles of AE-, β- and α-emitting radionuclides as a 
function of distance from a vessel of diameter 15 µm 
and active length of 40 µm is shown in Fig. 3. The 
maximum penetration depth of brain metastasis as 
noted from the immunohistochemistry results at day 
21 is ~50 µm from the edge of the vessel. Thus, the 
dose profiles of the different radionuclides were 
evaluated in terms of dose deposition over this 
distance from a vessel. Apart from 177Lu, 161Tb, and 
67Ga, the absorbed dose of all other electron emitters 
(AE and β emitters) decreased by more than 2 orders 
of magnitude over the first 50 µm from the vessel (Fig. 
3A). The ranking order of the electron emitters from 
highest to lowest total dose over the 50 µm distance 
were 161Tb, 177Lu, 90Y, 67Ga, 111In, 124I and 89Zr. If all of 
the electron-emitting radionuclides are constrained to 
have the same dose at the vessel (i.e., the normalized 
dose plot) the highest dose contribution over this 
distance arises from 177Lu. In the 40-60 µm region the 
dose deposition from 177Lu was comparable to that of 
90Y, but otherwise the normalized dose from 177Lu 
exceeded that of 90Y. On the other hand, for α-emitters 
(Fig. 3B), only 149Tb showed a decrease greater than 2 
orders of magnitude over this distance. The ranking 
for α-emitters was 225Ac, 211At, 212Pb, 213Bi and 149Tb. 
225Ac imparted an absorbed dose ~4 times higher than 
the other α-emitters for most distances, since it has 4 
α-particles in its decay chain. The differences between 
211At, 212Pb, and 213Bi (in terms of absolute dose) were 
small. The dose fall off from 212Pb was the furthest 
from the vessel compared to all other α-emitters, since 
it has the most energetic α-particle component. Dose 
decreased by 2 orders of magnitude from the vessel to 
about 85 µm, then another 2 orders of magnitude to 
~100 µm.  
 
 
Figure 2. (A) Immunohistochemical detection of brain metastases. Photomicrograph of tumor colonies showing co-localization of VCAM-1 (brown) with brain 
metastasis (violet) at day 21 after intra-cardiac injection of MDA231BR cells. (B) Summary statistics of the depth of penetration of cancer cells for vessels of different 
diameters. Box and whiskers plots of minimum to maximum values, showing the median and SD at each vessel diameter grouping. (C) 2-Photon microscopy of brain 
parenchyma and vessels (seen through viewing window) showing co-optive growth (white arrows) of GFP MDA231BR cells (green) around vessels (orange - TRITC) 
with maximal penetration from the vessel lumen in this slice, 17 µm.  






Figure 3. Absorbed dose profiles of each radionuclide for a vessel of 15 µm radius and length of 40 µm. Dose was normalised to the first bin with bin width set at 
1 µm. Data points represent the average and SD of 5 runs. Absorbed dose profiles for (A) AE and β-emitting radionuclides and (B) α-emitting radionuclides. Insets 
show the non-normalized dose (in Gy) per event.  
 
Figure 4. Dose per decay (Gy) for 177Lu. (A) Variation of absorbed dose (Gy) for a 15 µm diameter vessel as a function of vessel length. (B) Variation of absorbed 
dose (Gy) for a vessel of length 40 µm as a function of vessel diameter.  
 
To evaluate the effect of vessel diameter and 
active vessel length on absorbed dose, the dose 
deposition profiles for 177Lu and 212Pb are shown (Figs. 
4 and 5). For 177Lu, the dose per decay for longer 
vessels was lower than that of shorter vessels. For 
example, for vessel lengths of 20 μm and 100 μm this 
difference decreased from 73% at the vessel wall to 
21% at a radius of 57.5 µm (50 µm from vessel wall) 
(Fig. 4A). Increasing vessel diameter resulted in an 
almost 3-fold decrease in dose per decay over the first 
10 μm from the vessel wall; however, the difference 
was < 8% for radial distances between 20 μm and 100 
μm (Fig. 4B). Similarly for 212Pb, the difference 
between the dose per event for vessel lengths of 20 μm 
and 100 μm decreased from 72% at the vessel wall to 
15% at a radius of 57.5 μm (Fig. 5A), while the dose 
per event decreased up to 3-fold from a vessel length 
of 20 μm to 100 μm. An increase in vessel diameter 
resulted in a radial shift of dose deposition with a 59% 
decrease in dose per decay immediately adjacent to 
the vessel for the largest versus the smallest vessel 
radii. For greater distances the difference between the 
vessel diameters was typically smaller than the dose 
uncertainty, other than the steep fall off, which shifted 
in position based on the difference of diameters (Fig. 
5B).  
DNA strand break yield and RBE 
A summary of the DSB induction potential of 
177Lu vs. that of 212Pb is presented in Fig. 6. For 177Lu 
(Fig. 6A), the VOI dose contribution from photons 
over the considered range was negligible when 
compared to that from electrons. The total dose and 
DSB yield (Fig 6C) was mostly due to the contribution 
of electrons (β- -particles). On average, 177Lu produced 
2.69 ± 0.08 DSB per GbpGy. Over the distance 





considered, contributions from major groups of 
electrons to DSB induction resulted in fluctuations of 
< 10%.  
To fully understand the DSB profile of 212Pb, it is 
necessary to consider its physical decay scheme. 212Pb 
(10.6 h half-life) does not directly emit α-particles, but 
its daughters 212Bi and 212Po emit two α-particles 
during their decay. 212Pb decays to 212Bi via 
β-emission. In turn 212Bi (60 min half-life) decays to 
stable 208Pb through one of two possible paths, each of 
which passes through one intermediate nuclide, 
releasing one α-particle and one β-particle. For 36% of 
the time, 212Bi emits an α-particle of 6.1 MeV and 
decays to 208Tl, which in turn decays to 208Pb via 
β-emission. For the other 64% of the time, 212Bi decays 
to 212Po via β-emission, and 212Po then decays in 
microseconds to 208Pb by emission of an 8.8 MeV 
α-particle. The β-particles from 212Pb itself are lower 
energy (573 keV) than the β-particles from 212Bi (2.3 
MeV) and 208Tl (5 MeV), while the frequency and 
cumulative energy from the γ-emissions is < 12% of 
that from the α-particles. However a 238.6 keV γ-ray, 
with a 43% yield, can be exploited for imaging [34].  
 
 
Figure 5. Dose per event (Gy) for 212Pb. (A) Variation of absorbed dose (Gy) for a 15 µm diameter vessel as a function of vessel length. (B) Variation of absorbed 
dose (Gy) for a vessel of length 40 µm as a function of vessel diameter.  
 
Figure 6. A summary of the total dose (Gy) delivered by (A) 177Lu and (B) 212Pb in each VOI as a function of radial distance from a vessel with diameter 15 µm and 
active vessel length of 40 µm, DSB yield (per GbpGy) for (C) 177Lu and (D) 212Pb. Both the dose and DSB break yields were discriminated according to the associated 
primary decay particle, however contributions from electrons (green) and α-particles (red) may be are superimposed on the total yield (black). 






Figure 7. (A) Dose-average relative biological effectiveness for 177Lu and 212Pb. (B) Total number of DSB per decay and Gbp of 177Lu and 212Pb as a function of radius.  
 
As would be predicted, the main contribution to 
the VOI dose from the decay of 212Pb was due to the 
6.1 and 8.8 MeV α-emissions from 212Bi and 212Po 
respectively (Fig. 6B). Electron doses are about two 
orders of magnitude lower than dose attributable to 
α-particles and decrease exponentially on a log scale 
with distance. As shown in Fig. 6B, 6D, and 7B, the 
dose/DSB from the electrons continued on smoothly 
past 100 µm, but at orders of magnitude lower than 
dose/DSB due to α-particles. The contribution from 
photons to the dose and DSB yield (Fig. 6D) was 
negligible and the associated uncertainties were very 
high. For this reason, the contribution from photons 
was omitted from the DSB plot. The VOI dose 
fluctuated with radial distance, with two local 
maxima observed at ~40 μm and ~80 μm. These two 
regions are most evident in the DSB yields shown in 
Fig 6D. The peaks can be explained by the presence of 
the two α-particles arising from the decay of 212Bi and 
212Po, with projected ranges of 50.1 μm and 91.0 μm 
and associated DSB yields per GbpGy of 7.64 ± 0.12 
and 9.15 ± 0.24 respectively. It is important to note 
that the observed maxima are a consequence of the 
superposition of multiple Bragg peaks resulting from 
isotropically emitted α-particles on the vessel wall, 
and not a simple projection of ranges. DSB yields for 
electrons also show a very complex behaviour since 
there are many β and Auger components in the decay 
spectrum with different associated ranges. As a result, 
the electron DSB yield changes with distance from the 
vessel wall.  
Estimated RBE values were determined by only 
evaluating DNA damage due to physical interaction 
of the radionuclides in question. This was done in a 
consistent way, using the same biophysical model for 
the isotopes studied. The RBE obtained for each 
particle type at a given distance from the vessel axis 
was weighted by the corresponding dose fraction 
(Fig. 7A). For 177Lu, the contribution of electrons only, 
and for 212Pb the contributions of electrons and 
α-particles, were considered. In contrast to 212Pb, the 
dose-average RBE for 177Lu was lower than 1 (0.73 ± 
0.02), which means that electrons emitted during this 
decay have a RBE lower than that of 60Co. In addition, 
this was verified for photons where an RBE = 1 was 
obtained for the first 4 data points that had acceptable 
uncertainties (data not shown). The presence of 
α-particles in the 212Pb spectrum produced an 
appreciable departure of the dose-average RBE from 
1, i.e., 2.10 ± 0.18 and 2.52 ± 0.60, mainly around the 
maxima as a result of the superposition of the Bragg 
peaks. To appreciate the difference in DSB yield 
between 177Lu and 212Pb, the total number of DSB per 
decay and Gbp are shown in Fig. 7B. The DSB yield of 
212Pb per decay varies as a function of linear energy 
transfer (LET) and radial distance from the vessel. The 
DSB yield per decay ratio between 212Pb and 177Lu 
increases to 607.34 ± 60.40 and 826.09 ± 102.11 at the 
local maxima produced by the 6.1 MeV and 8.8 MeV 
α-emissions from 212Bi and 212Po respectively. 
Discussion 
The upregulation of cellular adhesion molecules 
on the endothelium of cerebral blood vessels, which 
results from tumor cell extravasation into the brain 
parenchyma, presents a promising biomarker for 
diagnosis and therapy [21, 35]. In particular, the use of 
radionuclide-based theranostic agents directed 
against adhesion molecules is an attractive prospect. 
However, extensive in vivo experimentation to 
elucidate which radiopharmaceutical could 
potentially offer the best dose-profile and therapeutic 
effect for this distinctive tumour morphology would 
be both time consuming and costly. These obstacles 
can be overcome, and the most promising 
radionuclides selected for further study, through the 
use of MC simulations applied to models that 
accurately represent the architecture of brain 





metastases. In the clinic, brain metastases frequently 
show a co-optive growth pattern irrespective of the 
primary tumour type and grow circumferentially 
around blood vessels [36]. The preclinical in vivo 
model MDA213BR, used in the current study, is 
entirely consistent with this pattern of growth. 
Realistic representations of MDA231BR metastases 
were constructed for MC simulation, reflecting the 
co-optive growth pattern and the depth of penetration 
of cancer cells as determined by 
immunohistochemistry and live 2-photon imaging 
(Fig. 2). Simulations were performed to evaluate the 
dose profiles of a panel of radionuclides. It is clear 
from the dose profiles (Fig. 3A and B) that the 
α-emitters offer an advantage over β- and 
AE-emitters. Interestingly, the normalized dose 
profile of 67Ga compared favourably with that of 90Y 
and 177Lu. However, the very low dose imparted by 
the AE-emitting nuclides 89Zr and 124I precludes them 
as therapeutic radionuclides in this situation but 
would make them suitable for PET imaging 
purposes.177Lu and 212Pb were then selected for 
further comparison and simulation as they showed 
the most uniform deposition of dose over 50 µm from 
the vessel wall, while 212Pb showed the furthest 
penetration (∼100 µm). 
A vessel diameter of 15 µm, at the upper end of 
the range for venous radii in mouse brain, was chosen 
for MC simulation to facilitate direct comparison with 
analogous vessel diameters in human brain (median 
range 16–32 µm) [37]. In fact, a change in vessel radius 
had only a minor effect on dose profiles as a function 
of radial distance for the two radionuclides chosen for 
in-depth study, 177Lu and 212Pb (Fig. 4 and 5). 
Furthermore, a 40 µm active vessel length was used 
for MC simulation although tumor growth was 
observed in up to 5 consecutive histology sections 
(section thickness of 20 µm – data not shown). This 
choice was informed not only by computation time, 
but also as a direct result of the simulation results 
(Fig. 4 and 5) where varying active vessel length due 
to the symmetry in the geometry did not greatly affect 
the dose profiles of 177Lu and 212Pb. In addition, as the 
dose measurement was limited to a disk of width 3.5 
µm to enable direct comparison with the dose 
measurement in the atomic DNA geometry model, 
the variation of dose for 177Lu and 212Pb was also 
measured over an active vessel length of 100 µm. Dose 
per decay showed a slight decrease at the edge of the 
active vessel due to the lack of charged particle 
equilibrium (Fig. S1). For both 177Lu and 212Pb, dose 
decreased by 25% from the mid-point to the end of the 
active vessel. However the initial falloff for 177Lu was 
slightly faster compared with that of 212Pb. The 
geometric model that was used captures the salient 
features of brain vasculature and the results of 
simulations were robust to changes in geometry. We 
infer that our results can be generalized from the 
mouse-model measurements to the human scale 
relevant to a clinical scenario.  
For theranostic purposes, the dose imparted per 
decay by α-emitting 212Pb was typically two orders of 
magnitude higher than for β-emitting 177Lu and this 
translated into higher DNA damage yields (Fig. 6). 
The short path length of α-particles render them 
particularly suitable for the treatment of 
micro-metastases or neoplastic disease that is present 
as single layers or sheets of cells on compartment 
surfaces [38]. High-LET radiation like α-particles 
produce dense ionizations along a linear track and 
generate multiply damaged sites in DNA. This is 
reflected in the higher DSB yields obtained for 212Pb 
(Fig. 6D) when compared to 177Lu (Fig. 6C). DSB yield 
(per GbpGy) for the former can be up to three times 
higher than for the latter. Supplementary Fig. S2 
shows the total strand break (TSB) yield, which is the 
total number of SSB produced by 177Lu or 212Pb, 
including those leading to DSB. As shown by others, 
SSB depends weakly on the incident radiation quality 
[39, 40]. Thus, regardless of the type of primary 
particle and its associated energy, a similar number of 
SSB per unit absorbed dose and base pair are 
produced. This, however, does not translate into the 
same RBE since the number of SSB that lead to DSB 
tends to increase with particle LET. 
The biophysical model used in the current study 
shows that 177Lu has a dose-average RBE lower than 1 
(0.73 ± 0.02), which means that it is less effective than 
60Co radiation (the reference quality used). Although 
the associated photons yielded an RBE = 1, they only 
had a negligible impact on the dose-averaged RBE. 
Indeed, the calculated RBE based on DSB yields from 
physical damage only is in good agreement with an 
experimentally determined RBE of 1 for 
177Lu-DOTATOC using 137Cs γ-radiation as the 
reference radiation [41]. On the other hand, the RBE of 
212Pb varied with radial distance and increased to 2.10 
± 0.18 and 2.52 ± 0.60 at the local maxima of the 6.1 
MeV and 8.8 MeV α-emissions from 212Bi and 212Po 
respectively. These values yield a relative 212Pb/177Lu 
RBE of 2.87 and 3.45, respectively. The RBE of 
α-particles ranges from 2 to 7, and therefore, 
α-particle irradiation is 2–7 times more 
therapeutically effective, or toxic, per unit of absorbed 
dose than photons or electron [38, 42, 43]. 
Furthermore, DSB yields per decay for 212Pb varies 
with depth and LET and can be up to two orders of 
magnitude higher than those for 177Lu at the local 
maxima of the α-emissions from 212Bi and 212Po. This 
new metric (DSB yield per decay), could be clinically 





more informative than DSB yield per unit of absorbed 
dose, since the former can be directly estimated from 
the administered activity and does not require 
convoluted dose calculations.  
Considering the favorable dose profile and DNA 
damage yields of 212Pb, it is a good potential candidate 
for TRT in early brain metastasis treatment and 
imaging. It has an intermediate physical half live of 
10.64 h compatible with clinical use [44] and emits 
γ-rays suitable for SPECT [45]. Furthermore, it is a 
practical choice because it is produced in a generator 
(224Ra/212Pb generator), and stable chelation is 
possible using TCMC (2-(4-isothiocyanatobenzyl- 
1,4,7,10tetraaza-1,4,7,10,tetra-(2-carbamonylmethyl)-c
yclododecane) [46]. Meredith and co-workers recently 
demonstrated the efficacy of intraperitoneal 
212Pb-TCMC-trastuzumab in a phase I trial in ovarian 
cancer patients with HER-2 expressing tumors [34]. 
Encouragingly the treatment caused little toxicity 
during follow-up for 1 year [47], possibly because of 
the containment of the radioimmunoconjugate within 
the peritoneal cavity. In addition, a decrease in 
tumor-associated glycoprotein 72 (TAG-72) and 
tumor growth was associated with increasing 
administered radioactivity. However, a potential 
problem when using an α-emitter with serial decay to 
α-emitting daughters, is that the recoil energy is 
sufficient to detach the daughters from the targeting 
vector [38]. In the case of 212Pb, the mononuclear 
complex produced between 212Pb and TCMC results 
in an extremely stable compound for in vivo use [48].  
All systemically administered therapeutics, 
including radiopharmaceuticals, that are designed to 
treat brain metastases face common obstacles: the 
need for delivery across the blood-brain barrier (BBB) 
and the need to reach the molecular target in adequate 
concentration [49]. The issue of access to metastatic 
sites behind an intact BBB is being addressed using a 
number of different approaches. For example, Connell 
et al. demonstrated that it is possible to selectively 
permeabilize the BBB at metastatic sites through 
systemic cytokine administration, thus facilitating 
delivery of therapeutic agents across the BBB [50]. 
Similarly, a recent proof-of-concept study using 
convection-enhanced delivery of an AE-emitting 
radionuclide in an orthotopic xenograft glioblastoma 
model showed great promise to overcome the 
limitations of systemic delivery of TRTs [51]. 
However, the intrinsic sensitivity of tumor cells to the 
radio-pharmacologic agent is likely to be the most 
important determinant of its therapeutic success [4]. 
In this regard targeted α-particle therapy offers a 
distinct advantage.  
Conclusion 
The dimensions and 3D shape of early brain 
metastasis and their associated blood vessels were 
used to build an in silico replica. The model was 
designed to mimic targeting of VCAM-1, an 
endothelial marker of cancer cell invasion, by 
radioimmunoconjugates. In this respect, MC 
simulation has allowed selection of the radioisotope 
with the most suitable dose profile for treatment in a 
specific case, that is, early brain metastases. However, 
it would be possible to apply a similar approach to 
cancer lesions at other anatomical sites that have 
different morphology provided that the location of 
the target molecule and the physical dimensions of 
relevant structures such as blood vessels are known. 
212Pb, which has the attributes of a theranostic 
radionuclide since it can be used for SPECT imaging, 
showed a favorable dose profile and RBE.  
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